<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925272</url>
  </required_header>
  <id_info>
    <org_study_id>2010-06</org_study_id>
    <secondary_id>1006</secondary_id>
    <nct_id>NCT03925272</nct_id>
  </id_info>
  <brief_title>Creation of a Prospective Cohort of Healthy and Sick Subjects and of a Collection of Associated Biological Resources, for the Study of the Immune System and of Its Genetic and Environmental Determinants.</brief_title>
  <acronym>CoSImmGEn</acronym>
  <official_title>Constitution d'Une Cohorte Prospective de Sujets Sains et Malades et d'Une Collection de Ressources Biologiques associées Pour l'étude du système Immunitaire et de Ses déterminants Génétiques et Environnementaux&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Pasteur</source>
  <brief_summary>
    <textblock>
      CoSImmGEn is a protocol set up to respond to the current lack of healthy and sick population
      cohorts. Biological resources from these cohorts allow researchers to study the immune system
      and its genetic and environmental determinants. Those cohorts and collections are open not
      only to the Pasteurian community but also to the worldwide scientific community (both public
      and private) working in the field.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CoSImmGEn protocol is dedicated to the study of the immune system in healthy people or
      people with specific pathologies. It is composed of 6 arms (sub-cohorts):

        -  Arm &quot;main cohort CoSImmGEn&quot;: comprised of 5 sub groups (A, B, C, D, M) of healthy adult
           subjects from various ethno-geographical origins.

        -  Arm &quot;ancillary cohort P&quot; comprised of first-degree relatives (including parents,
           siblings, or children), whether they are healthy or ill. It will allow, whenever
           necessary, to remove allelic ambiguities for example for the study of HLA and MHC genes.

        -  Arm &quot;ancillary cohort HS&quot;: comprised of subjects suffering from Suppurativa Hidradenitis
           (or Verneuil's disease.) The investigators will include patients suffering from this
           disease and their close relatives, in order to understand the genetic, immunological,
           microbiological and metabolomic bases of this disease.

        -  Arm &quot;ancillary cohort J&quot;: comprised of elderly patients (≥ 65 years old) with
           Alzheimer's disease and with mild, moderate or severe cognitive impairment. It will help
           understand the role of the gut microbiota in age-related brain deficits.

        -  Arm &quot;ancillary cohort F&quot;: comprised of patients with familial adenomatous polyposis and
           carrying a mutation of the APC (Adenomatous Polyposis Coli) tumor suppressor gene. That
           arm has been set up to carry out a pilot phase on the role of APC mutations on
           anti-tumoral immune response.

        -  Arm &quot;ancillary cohort I&quot;: comprised of patients with chronic inflammatory diseases such
           as Ankylosing spondylitis and Crohn's disease.

      Additional arms may be set up through new collaborations in the next few years to study
      others diseases in which the immune system intervenes, such as: infectious diseases,
      allergies or cancers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2011</start_date>
  <completion_date type="Anticipated">December 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological analysis</measure>
    <time_frame>through study completion, an average of 4 year</time_frame>
    <description>Percentage of blood cells harbouring morphological of functional abnormalities identified by flow cytometry and TrueCulture system analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic analysis</measure>
    <time_frame>through study completion, an average of 4 year</time_frame>
    <description>Identification of genetic factors implicated in or predisposing to specific diseases through gene expression quantification, targeted genotyping of exome sequencing or whole genome sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota analysis</measure>
    <time_frame>through study completion, an average of 4 year</time_frame>
    <description>Identification of specific compositions of intestinal and/or cutaneous microbiota associated with specific diseases by metagenomic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic analysis</measure>
    <time_frame>through study completion, an average of 4 year</time_frame>
    <description>Quantification of blood metabolites by mass spectrometry</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Immune System and Related Disorders</condition>
  <arm_group>
    <arm_group_label>Patients with Suppurated Hidradenitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human biological samples :
Whole blood and derived products (DNA, RNA), urine, stool, saliva, tears, skin and mouth swabs, lesion samples: swab for microbiological analyzes, cutaneous biopsies (lesion skin and peri-lesional healthy skin), surgical lesion excisions.
bio-clinical data: Ethno-geographical, family and personal antecedents and current events in particular related to Verneuil's disease and any associated diseases (chronic auto-inflammatory ...)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Alzheimer disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human biological samples :
stool, blood (20 ml)
bio-clinical data: healthy or sick status,cognitive, memory and psychometric abilities evaluated by different tests example: MMSE (for Alzheimer's) and MST (minor memory disorders), Psychometric abilities assessed by the Geriatric Depression Scale GDS, Nutritional status assessed by the MNA test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with familial adenomatous polyposis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human biological samples :
whole blood (30 to 100 mL), optional stool collection
bio-clinical data: Age, Gender, Ethnicity, Personal and Family Medical History, Current Treatment, Type of PAF Mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with chronic inflammatory diseases (SPA, Crohn, ...)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human biological samples :
whole blood and derived products (DNA, RNA, PBMC, plasma, serum), (100 mL), stool; as part of the treatment, occasionally: lesions, urine, saliva, tears
Bio-clinical data :
Ethno-geographical origin, Personal and family history, History of the disease, Associated or concomitant diseases, Treatments in progress.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy cases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human biological samples :
whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions
Bio-clinical data :
ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ...</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy cases relatives</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human biological samples :
whole blood and derived products: serum, plasma, DNA, RNA, PBMCs, T and B lymphocytes, monocytes / dendritic cells derived, other subpopulations (PMN, NK, etc.), urine, stool, saliva, tears, oral swabs, cutaneous swabs (healthy and injured), cutaneous biopsies (healthy and injured) and their derivatives (RNA, histological blocks ...), surgical excisions
Bio-clinical data :
ethno-geographical origin (5 groups), family and personal antecedents and contemporary events visits, in particular related to the immune system, infections, vaccinations, exposure factors (travel, lifestyles, stress, pollution cancers, allergies , chronic inflammatory diseases ...</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of samples (blood, stool, etc.)</intervention_name>
    <arm_group_label>Healthy cases</arm_group_label>
    <arm_group_label>Healthy cases relatives</arm_group_label>
    <arm_group_label>Patients with Alzheimer disease</arm_group_label>
    <arm_group_label>Patients with Suppurated Hidradenitis</arm_group_label>
    <arm_group_label>Patients with chronic inflammatory diseases (SPA, Crohn, ...)</arm_group_label>
    <arm_group_label>Patients with familial adenomatous polyposis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic determinants analysis</intervention_name>
    <arm_group_label>Healthy cases</arm_group_label>
    <arm_group_label>Healthy cases relatives</arm_group_label>
    <arm_group_label>Patients with Alzheimer disease</arm_group_label>
    <arm_group_label>Patients with Suppurated Hidradenitis</arm_group_label>
    <arm_group_label>Patients with chronic inflammatory diseases (SPA, Crohn, ...)</arm_group_label>
    <arm_group_label>Patients with familial adenomatous polyposis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sample obtained after surgery performed in the context of care</intervention_name>
    <arm_group_label>Patients with Suppurated Hidradenitis</arm_group_label>
    <arm_group_label>Patients with chronic inflammatory diseases (SPA, Crohn, ...)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unprotected adults with social security who have attested their consent after
             receiving any relevant information about the study

          -  subjects whose ethno-geographical origin of both parents is known

          -  subjects for whom data on principal vaccinations (diphtheria, tetanus, poliomyelitis,
             hepatitis B, possibly tuberculosis) are documented

          -  subjects who consented to carry out serological tests HIV, HCV, HBV

        Exclusion Criteria:

          -  Any conditions that would not allow participation in the present study, on the opinion
             of the investigator (documenting), ie any acute or chronic pathology that may
             interfere with the immune system, such as progressive or chronic pathology severe or
             uncontrolled by current treatments or a pathology requiring the administration of
             immune impact drugs: long-term anti-inflammatory, immunosuppressive, etc

          -  Pregnant or lactating women

          -  For the realization of skin biopsies: allergy to local anesthetics, cardiac
             valvulopathy

          -  For the realization of Tubertest: Subject presenting a contraindication to tuberculin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Noelle Ungeheuer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Pasteur - ICAReB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Noelle Ungeheuer, PhD</last_name>
    <phone>+33 0140613581</phone>
    <email>marie-noelle.ungeheuer@pasteur.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Laude, PhD</last_name>
    <phone>+33 0145688395</phone>
    <email>helene.laude@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre médical de l'Institut Pasteur</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude Nassif, PhD</last_name>
      <phone>0140613077</phone>
      <email>aude.nassif@pasteur.fr</email>
    </contact>
    <contact_backup>
      <last_name>Maia Delage-Toriel, PhD</last_name>
      <phone>0145688214</phone>
      <email>maia.delage-toriel@pasteur.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Pasteur</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Noelle Ungeheuer, PhD</last_name>
      <phone>0140613581</phone>
      <email>marie-noelle.ungeheuer@pasteur.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hélène Laude, PhD</last_name>
      <phone>0145688394</phone>
      <email>helene.laude@pasteur.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital sainte Périne</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joelle Brachat, PhD</last_name>
      <phone>0144963217</phone>
      <email>joelle.brachat@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Dany Vythilingum, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Iglesias MC, Briceno O, Gostick E, Moris A, Meaudre C, Price DA, Ungeheuer MN, Saez-Cirion A, Mallone R, Appay V. Immunodominance of HLA-B27-restricted HIV KK10-specific CD8(+) T-cells is not related to naïve precursor frequency. Immunol Lett. 2013 Jan;149(1-2):119-22. doi: 10.1016/j.imlet.2012.10.002. Epub 2012 Oct 13.</citation>
    <PMID>23068784</PMID>
  </reference>
  <reference>
    <citation>Duffy D, Rouilly V, Libri V, Hasan M, Beitz B, David M, Urrutia A, Bisiaux A, Labrie ST, Dubois A, Boneca IG, Delval C, Thomas S, Rogge L, Schmolz M, Quintana-Murci L, Albert ML; Milieu Intérieur Consortium. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity. 2014 Mar 20;40(3):436-50. doi: 10.1016/j.immuni.2014.03.002.</citation>
    <PMID>24656047</PMID>
  </reference>
  <reference>
    <citation>Thomas S, Rouilly V, Patin E, Alanio C, Dubois A, Delval C, Marquier LG, Fauchoux N, Sayegrih S, Vray M, Duffy D, Quintana-Murci L, Albert ML; Milieu Intérieur Consortium. The Milieu Intérieur study - an integrative approach for study of human immunological variance. Clin Immunol. 2015 Apr;157(2):277-93. doi: 10.1016/j.clim.2014.12.004. Epub 2015 Jan 3.</citation>
    <PMID>25562703</PMID>
  </reference>
  <reference>
    <citation>Monceaux V, Chiche-Lapierre C, Chaput C, Witko-Sarsat V, Prevost MC, Taylor CT, Ungeheuer MN, Sansonetti PJ, Marteyn BS. Anoxia and glucose supplementation preserve neutrophil viability and function. Blood. 2016 Aug 18;128(7):993-1002. doi: 10.1182/blood-2015-11-680918. Epub 2016 Jul 8.</citation>
    <PMID>27402974</PMID>
  </reference>
  <reference>
    <citation>Urrutia A, Duffy D, Rouilly V, Posseme C, Djebali R, Illanes G, Libri V, Albaud B, Gentien D, Piasecka B, Hasan M, Fontes M, Quintana-Murci L, Albert ML; Milieu Intérieur Consortium. Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses. Cell Rep. 2016 Sep 6;16(10):2777-2791. doi: 10.1016/j.celrep.2016.08.011. Epub 2016 Aug 25.</citation>
    <PMID>27568558</PMID>
  </reference>
  <reference>
    <citation>Hamimi C, David A, Versmisse P, Weiss L, Bruel T, Zucman D, Appay V, Moris A, Ungeheuer MN, Lascoux-Combe C, Barré-Sinoussi F, Muller-Trutwin M, Boufassa F, Lambotte O, Pancino G, Sáez-Cirión A; ANRS CO21 CODEX cohort. Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles. PLoS One. 2016 Aug 9;11(8):e0160251. doi: 10.1371/journal.pone.0160251. eCollection 2016.</citation>
    <PMID>27505169</PMID>
  </reference>
  <reference>
    <citation>Duffy D, Rouilly V, Braudeau C, Corbière V, Djebali R, Ungeheuer MN, Josien R, LaBrie ST, Lantz O, Louis D, Martinez-Caceres E, Mascart F, Ruiz de Morales JG, Ottone C, Redjah L, Guen NS, Savenay A, Schmolz M, Toubert A, Albert ML; Multinational FOCIS Centers of Excellence. Standardized whole blood stimulation improves immunomonitoring of induced immune responses in multi-center study. Clin Immunol. 2017 Oct;183:325-335. doi: 10.1016/j.clim.2017.09.019. Epub 2017 Sep 22.</citation>
    <PMID>28943400</PMID>
  </reference>
  <reference>
    <citation>Piasecka B, Duffy D, Urrutia A, Quach H, Patin E, Posseme C, Bergstedt J, Charbit B, Rouilly V, MacPherson CR, Hasan M, Albaud B, Gentien D, Fellay J, Albert ML, Quintana-Murci L; Milieu Intérieur Consortium. Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E488-E497. doi: 10.1073/pnas.1714765115. Epub 2017 Dec 27.</citation>
    <PMID>29282317</PMID>
  </reference>
  <reference>
    <citation>Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, Alanio C, Scepanovic P, Hammer C, Jönsson F, Beitz B, Quach H, Lim YW, Hunkapiller J, Zepeda M, Green C, Piasecka B, Leloup C, Rogge L, Huetz F, Peguillet I, Lantz O, Fontes M, Di Santo JP, Thomas S, Fellay J, Duffy D, Quintana-Murci L, Albert ML; Milieu Intérieur Consortium. Publisher Correction: Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Nat Immunol. 2018 Jun;19(6):645. doi: 10.1038/s41590-018-0105-3.</citation>
    <PMID>29725081</PMID>
  </reference>
  <reference>
    <citation>Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E, Thorball CW, Chaturvedi N, Charbit B, Abel L, Quintana-Murci L, Duffy D, Albert ML, Fellay J; Milieu Intérieur Consortium. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018 Jul 27;10(1):59. doi: 10.1186/s13073-018-0568-8.</citation>
    <PMID>30053915</PMID>
  </reference>
  <reference>
    <citation>Kilens S, Meistermann D, Moreno D, Chariau C, Gaignerie A, Reignier A, Lelièvre Y, Casanova M, Vallot C, Nedellec S, Flippe L, Firmin J, Song J, Charpentier E, Lammers J, Donnart A, Marec N, Deb W, Bihouée A, Le Caignec C, Pecqueur C, Redon R, Barrière P, Bourdon J, Pasque V, Soumillon M, Mikkelsen TS, Rougeulle C, Fréour T, David L; Milieu Intérieur Consortium. Parallel derivation of isogenic human primed and naive induced pluripotent stem cells. Nat Commun. 2018 Jan 24;9(1):360. doi: 10.1038/s41467-017-02107-w.</citation>
    <PMID>29367672</PMID>
  </reference>
  <reference>
    <citation>Belizna C, Stojanovich L, Cohen-Tervaert JW, Fassot C, Henrion D, Loufrani L, Nagy G, Muchardt C, Hasan M, Ungeheuer MN, Arnaud L, Alijotas-Reig J, Esteve-Valverde E, Nicoletti F, Saulnier P, Godon A, Reynier P, Chrétien JM, Damian L, Omarjee L, Mahé G, Pistorius MA, Meroni PL, Devreese K. Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities? Autoimmun Rev. 2018 Aug;17(8):739-745. doi: 10.1016/j.autrev.2018.01.027. Epub 2018 Jun 6. Review.</citation>
    <PMID>29885541</PMID>
  </reference>
  <reference>
    <citation>Belizna C, Pregnolato F, Abad S, Alijotas-Reig J, Amital H, Amoura Z, Andreoli L, Andres E, Aouba A, Apras Bilgen S, Arnaud L, Bienvenu B, Bitsadze V, Blanco P, Blank M, Borghi MO, Caligaro A, Candrea E, Canti V, Chiche L, Chretien JM, Cohen Tervaert JW, Damian L, Delross T, Dernis E, Devreese K, Djokovic A, Esteve-Valverde E, Favaro M, Fassot C, Ferrer-Oliveras R, Godon A, Hamidou M, Hasan M, Henrion D, Imbert B, Jeandel PY, Jeannin P, Jego P, Jourde-Chiche N, Khizroeva J, Lambotte O, Landron C, Latino JO, Lazaro E, de Leeuw K, Le Gallou T, Kiliç L, Limper M, Loufrani L, Lubin R, Magy-Bertrand N, Mahe G, Makatsariya A, Martin T, Muchardt C, Nagy G, Omarjee L, Van Paasen P, Pernod G, Perrinet F, Pïres Rosa G, Pistorius MA, Ruffatti A, Said F, Saulnier P, Sene D, Sentilhes L, Shovman O, Sibilia J, Sinescu C, Stanisavljevic N, Stojanovich L, Tam LS, Tincani A, Tollis F, Udry S, Ungeheuer MN, Versini M, Cervera R, Meroni PL. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmun Rev. 2018 Dec;17(12):1153-1168. doi: 10.1016/j.autrev.2018.05.012. Epub 2018 Oct 12. Review.</citation>
    <PMID>30316994</PMID>
  </reference>
  <reference>
    <citation>Prigent J, Lorin V, Kök A, Hieu T, Bourgeau S, Mouquet H. Scarcity of autoreactive human blood IgA(+) memory B cells. Eur J Immunol. 2016 Oct;46(10):2340-2351. doi: 10.1002/eji.201646446. Epub 2016 Aug 25.</citation>
    <PMID>27469325</PMID>
  </reference>
  <reference>
    <citation>Bouchet J, Del Río-Iñiguez I, Vázquez-Chávez E, Lasserre R, Agüera-González S, Cuche C, McCaffrey MW, Di Bartolo V, Alcover A. Rab11-FIP3 Regulation of Lck Endosomal Traffic Controls TCR Signal Transduction. J Immunol. 2017 Apr 1;198(7):2967-2978. doi: 10.4049/jimmunol.1600671. Epub 2017 Feb 24.</citation>
    <PMID>28235866</PMID>
  </reference>
  <reference>
    <citation>Agüera-González S, Burton OT, Vázquez-Chávez E, Cuche C, Herit F, Bouchet J, Lasserre R, Del Río-Iñiguez I, Di Bartolo V, Alcover A. Adenomatous Polyposis Coli Defines Treg Differentiation and Anti-inflammatory Function through Microtubule-Mediated NFAT Localization. Cell Rep. 2017 Oct 3;21(1):181-194. doi: 10.1016/j.celrep.2017.09.020.</citation>
    <PMID>28978472</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune system</keyword>
  <keyword>environmental interactions</keyword>
  <keyword>genetic component</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

